Abstract
Background The role of ambient temperature in the spread of SARS-CoV-2 infections and subsequent deaths due to COVID-19 remains contentious. Coronaviruses such as the 2003 SARS-CoV showed an increased risk of transmission during cooler days. We sought to analyse the effects of ambient temperature on SARS-COV-2 transmission and deaths related to the virus.
Methods The world population of COVID-19 cases and attributable deaths from the 23rd January 2020 to 11th April 2020 were analysed. Temperature 5 days before cases and 23 days prior to deaths (to account for the time lag of incubation period and time from symptoms to death) was compared to the average temperature experienced by the world population.
Results The total number of cases during this period was 1,605,788 and total number of deaths was 103,471. The median temperature at the time of COVID-19 infection was 9.12°C (10–90th percentile 4.29–17.97°C) whilst the median temperature of the world population for the same period was 9.61°C warmer at 18.73°C (10–90th percentile 4.09-28.49°C) with a notional p-value =5.1 x10−11. The median temperature at the time of a COVID-19 death was 9.72°C (10–90th percentile 5.39–14.11°C) whilst the median temperature of the world population was 7.55°C warmer at 17.27°C (10–90th percentile 2.57°C-27.76°C) with a notional p-value = 1.1 x10−10. 80% of all COVID-19 related cases and deaths occurred between 4.29°C and 17.97°C.
Conclusion A definitive association between infection rate and death from COVID-19 and ambient temperature exists, with the highest risk occurring around 9°C. Governments should maintain vigilance with containment strategies when the ambient temperatures correspond to this highest risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.